Prevention of Bronchiectasis in Infants With Cystic Fibrosis
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The general aim of this project is to conduct a randomized, double-blind, placebo-controlled
clinical trial of azithromycin to determine whether treatment from infancy is safe and will
prevent the onset of bronchiectasis. One hundred and thirty infants will be recruited from CF
clinics in Australia and New Zealand and treated from 3 months to three years of age. The
primary outcome will be the proportion with radiologically-defined bronchiectasis at 3 years
of age. Safety and mechanistic evaluations will also be undertaken.
Phase:
Phase 3
Details
Lead Sponsor:
Queensland Children's Medical Research Institute The University of Queensland